Hurel, a provider of artificial tissue constructs and microfluidic cell-based assay platforms, has raised $9.2 million in Series A financing. The equity came from lead investor Spring Mountain Capital and individual investors, and will go to support the company’s commercial launch of current products. Hurel will also continue research and development efforts toward its technologies and future products. Based in Beverly Hills and North Brunswick, NJ, Hurel develops products that improve the predictive reliability and overall efficiency of pre-clinical drug development. Spring Mountain used its SMC Select Co-Investment Fund I in the financing.